ArticleFrontiers in cardiovascular medicine2025
Case Report: ECMO rescue for cardiac arrest in a hyperthyroid patient triggered by COVID-19 infection.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a global pandemic, while both fulminant myocarditis (FM) and thyroid storm (TS) are life-threatening critical conditions. When these three conditions coexist in a single patient, the survival outcome can be severely compromised. Case introduction: We report a case of cardiac arrest in a hyperthyroid patient triggered by COVID-19 infection. The patient developed symptoms such as fatigue, chest tightness, and chest pain following SARS-CoV-2 infection, and experienced respiratory and CA en route to the hospital. Ultimately, the patient was diagnosed with FM and TS. The patient was treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) combined with continuous renal replacement therapy (CRRT). After hemodynamic stabilization, the patient received pharmacological management for arrhythmia control and hyperthyroidism, along with other symptomatic treatments. The patient eventually recovered and was discharged. Conclusion: In hyperthyroid patients infected with SARS-CoV-2, clinicians should remain vigilant for the potential development of FM and TS. VA-ECMO combined with CRRT represents an effective therapeutic approach in such critical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.